TABLE 1:

Sequence Parameters for Imaging Protocol 813

Imaging Details	Sequence 1a	Sequence 2b	Sequence 3c	Sequence 4d
Unenhanced and gadolinium-enhanced MRI
Contrast	Unenhanced	Unenhanced	Unenhanced	Contrast-enhanced
Image type	T1-weighted sagittal FFE	T1-weighted axial SE	T2-weighted axial TSE	T1-weighted MP-RAGE sagittal 3D TFE
FOV (mm)	180 × 240	180 × 240	180 × 240	230 × 230
Matrix	192 × 256	192 × 256	192 × 256	230 × 230
Slice thickness (mm)e	3	3	3	1
Ferumoxytol-enhanced MRI
Image type	T1-weighted sagittal FFE	T1-weighted axial SE	T2-weighted axial TSE	T1-weighted MP-RAGE sagittal 3D TFE
FOV (mm)	180 × 240	180 × 240	180 × 240	230 × 230
Matrix	192 × 256	192 × 256	192 × 256	230 × 230
Slice thickness (mm)e	3	3	3	1

Note—For all study subjects, gadolinium-enhanced MRI examinations were performed immediately after administration of a standard 0.1 mmol/kg IV dose of gadoteridol. For ferumoxytol-enhanced MRI, baseline T1-weighted unenhanced imaging was performed on day 1 immediately before ferumoxytol injection. Ferumoxytol-enhanced MRI was performed 24 hours after IV injection of 510 mg of ferumoxytol diluted in normal saline to optimize anatomic enhancement detection (on day 2). FFE = fast-field echo, SE = spin echo, TSE = turbo spin echo, MP-RAGE = magnetization-prepared rapid acquisition gradient echo, TFE = turbo field echo.

^aTR, 300 ms; number of signals acquired, 4.

^bTR/TE, 700/14; number of signals acquired, 1.

^cR/TE, 9000/72; number of signals acquired, 1.

^dTR/TE, 8.2/3.8; number of signals acquired, 1; flip angle, 8°.

^eAll sections were contiguous and interleaved.